Drug Trial Radar · NCT03712345
Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA
Last checked: Nov 19, 2026Latest source record: May 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
20
Actual
Start
Oct 15, 2018
Primary completion
Sep 10, 2020
Study completion May 3, 2021
Sponsor
- Lead sponsor
- InflaRx GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- IQVIA Pty Ltd
- First posted
- Oct 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety and tolerability of two dose regimens of IFX-1 as add-on to standard of care (SOC) in subjects with GPA and MPA compared with placebo.
Conditions
- Granulomatosis With Polyangiitis (GPA)
- Microscopic Polyangiitis (MPA)
Interventions
IFX-1 low doseDrug
Single IV infusions of IFX-1
IFX-1 high doseDrug
Single IV infusions of IFX-1
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number and Percentage of Participants With at Least One TEAE Per Treatment Group.Time frame: Week 24
Locations
38 sites in 2 countries. Site status is shown where the registry gives one.
Mayo Clinic Scottsdale
Scottsdale, Arizona
Loma Linda University Clinical Trial Center
Loma Linda, California
Science Connections, LLC
Doral, Florida
University of Miami
Miami, Florida
Rush University Medical Center
Chicago, Illinois
University of Kansas Medical Center Research Institute, Inc.
Kansas City, Kansas
LSU Health Sciences Center Shreveport
Shreveport, Louisiana
Johns Hopkins Bayview Medical Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
University Of MI Medcl Ctr-RHU
Ann Arbor, Michigan
Henry Ford Hospital
Detroit, Michigan
University of Minnesota
Minneapolis, Minnesota
Mayo Clinic
Rochester, Minnesota
Washington University
St Louis, Missouri
University of New Mexico
Albuquerque, New Mexico
Northwell Health, LLC PRIME
New Hyde Park, New York
Hospital for Special Surgery
New York, New York
University of Rochester Medical Center - Strong Memorial Hospital
Rochester, New York
UNC Kidney Center, UNC-CH Division of Nephrology and Hypertension
Chapel Hill, North Carolina
Trinity Medical Group
Minot, North Dakota
Ohio State University Clinical Trials Management Office
Columbus, Ohio
Oregon Health & Science University
Portland, Oregon
BRCR Medical Center, Inc.
Camp Hill, Pennsylvania
Altoona Center for Clinical Research, P.C.
Duncansville, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Rhode Island Hospital
Providence, Rhode Island
Low Country Rheumatology, PA
North Charleston, South Carolina
Adriana Pop Moody Clinic PA
Corpus Christi, Texas
Texas Health Resources
Dallas, Texas
Texas Research Institute
Fort Worth, Texas
Pioneer Research Solutions, Inc.
Houston, Texas
UVA University Physicians Charlottesville
Charlottesville, Virginia
West Virginia University
Morgantown, West Virginia
University of Alberta Hospital
Edmonton, Alberta, Canada
St. Josephs Healthcare
Hamilton, Ontaria, Canada
Mount Sinai Hospital
Toronto, Ontario, Canada
CHUM Centre de Recherche
Québec, Quebec, Canada
Centre de Recherche Musculo-Squelettique
Trois-Rivières, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.